Physician profile
Andrew K Chen
NPI 1134357007
$11,112.31
in general payments reported to CMS, 2019-2025
26 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,935 · 2020: $133 · 2021: $711 · 2022: $1,674 · 2023: $1,914 · 2024: $1,796 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Travel and Lodging: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,613.41 |
| Travel and Lodging | $2,044.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,941.04 | 2022-2025 | Micra, Onyx Frontier, Azure Xt Dr Mri Surescan |
| Biotronik INC. | $2,873.31 | 2019-2024 | Amvia Edge, Biomonitor |
| Biosense Webster, INC. | $1,558.67 | 2022-2025 | Carto 3, Qdot Micro Catheter, Soundstar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $490.36 | 2019-2023 | Lifevest |
| Abbott Laboratories | $380.82 | 2019-2023 | Aveir |
| Astrazeneca Pharmaceuticals LP | $331.19 | 2019-2025 | Lokelma |
| Medtronic Vascular, INC. | $231.53 | 2019 | |
| Medical Device Business Services, INC. | $218.33 | 2022 | |
| Boston Scientific Corporation | $154.44 | 2023-2024 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, Rezum Generator |
| Pfizer INC. | $121.01 | 2023-2025 | |
| Philips North America LLC | $118.86 | 2020-2024 | (Ck4) Mcot |
| Novartis Pharmaceuticals Corporation | $111.25 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $89.07 | 2024 | Optimizer |
| Biogen, INC. | $88.25 | 2021 | |
| United Therapeutics Corporation | $74.76 | 2024-2025 | Tyvaso, Tyvaso |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $53.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.27 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $45.89 | 2022-2025 | Verquvo |
| Amgen INC. | $41.81 | 2020-2021 | |
| Novo Nordisk INC | $24.97 | 2023 | Ozempic, Rybelsus |
| Cordis US Corp. | $23.45 | 2024 | Mynxgrip |
| Janssen Pharmaceuticals, INC | $20.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.27 | 2019 | |
| Cvrx, INC. | $17.42 | 2024 | Barostim Neo System |
| Irhythm Technologies, INC. | $15.87 | 2022 | |
| Hydrofera LLC | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.